2.7.1.4 Lipid modifying drugs, other
Expand All / Expand All (incl. cost)
Can be initiated in primary or secondary care when prescribed in accordance with NICE TA805 https://www.nice.org.uk/guidance/ta805 . Kent and Medway Prescribing Guidance is under development.
| Pack | Price |
|---|---|
| 120 capsule | £144.21 |
Approved in line with NICE TA733 for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults (only in patients with history of cardiovascular events)
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £50.00 |
Documents
-
Primary Care
-
Secondary Care
-
Primary and Secondary Care
Alirocumab & Evoculumab, GP update on Implementation of NICE TAs 393 & 394, Nov 2017
Uploaded By:
Renewal: 06/2019
Approved: 06/2019
Last Reviewed: 06/2019
Caution: This document is due for renewal and may be out of date
Document linked to:
| Drug | Section |
|---|---|
| Alirocumab |
2.7.1.4 Lipid modifying drugs, other
|
| Evolocumab |
2.7.1.4 Lipid modifying drugs, other
|
EKPG Recommendation - Evolocumab and alirocumab for hypercholesterolaemia
Uploaded By:
Renewal: 01/2021
Approved: 01/2018
Last Reviewed: 01/2018
Caution: This document is due for renewal and may be out of date
Document linked to:
| Drug | Section |
|---|---|
| Alirocumab |
2.7.1.4 Lipid modifying drugs, other
|
| Evolocumab |
2.7.1.4 Lipid modifying drugs, other
|
This is a hospital only medication. Referrals should be made to an endocrinologist. EKPG Recommendation can be viewed here: http://www.eastkentformulary.nhs.uk/media/1138/ekpg-recommendation-evolocumab-and-alirocumab-for-hypercholesterolaemia.pdf
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | |
| 2 pre-filled disposable injection | £336.00 |
This is a hospital only medication. Referrals should be made to an endocrinologist.EKPG Recommendation can be viewed here: http://tinyurl.com/ll4vafp
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | |
| 2 pre-filled disposable injection | £336.00 |
Documents
-
Primary Care
-
Secondary Care
-
Primary and Secondary Care
Alirocumab & Evoculumab, GP update on Implementation of NICE TAs 393 & 394, Nov 2017
Uploaded By:
Renewal: 06/2019
Approved: 06/2019
Last Reviewed: 06/2019
Caution: This document is due for renewal and may be out of date
Document linked to:
| Drug | Section |
|---|---|
| Alirocumab |
2.7.1.4 Lipid modifying drugs, other
|
| Evolocumab |
2.7.1.4 Lipid modifying drugs, other
|
EKPG Recommendation - Evolocumab and alirocumab for hypercholesterolaemia
Uploaded By:
Renewal: 01/2021
Approved: 01/2018
Last Reviewed: 01/2018
Caution: This document is due for renewal and may be out of date
Document linked to:
| Drug | Section |
|---|---|
| Alirocumab |
2.7.1.4 Lipid modifying drugs, other
|
| Evolocumab |
2.7.1.4 Lipid modifying drugs, other
|
This is a hospital only medication. Referrals should be made to an endocrinologist. EKPG Recommendation can be viewed here: http://www.eastkentformulary.nhs.uk/media/1138/ekpg-recommendation-evolocumab-and-alirocumab-for-hypercholesterolaemia.pdf
| Pack | Price |
|---|---|
| 2 pre-filled disposable injection | £340.20 |
Lomitapide is not recommended due to limited data and lack of evidence on cost effectiveness EKPG August 2013. Applications could be made by consultants via the Individual Funding Request (IFR) route if a particular patient was felt to meet the criteria for exceptionality.
| Pack | Price |
|---|---|
| 28 capsule |
Lomitapide is not recommended due to limited data and lack of evidence on cost effectiveness EKPG August 2013. Applications could be made by consultants via the Individual Funding Request (IFR) route if a particular patient was felt to meet the criteria for exceptionality.
| Pack | Price |
|---|---|
| 28 capsule |
Lomitapide is not recommended due to limited data and lack of evidence on cost effectiveness EKPG August 2013. Applications could be made by consultants via the Individual Funding Request (IFR) route if a particular patient was felt to meet the criteria for exceptionality.
| Pack | Price |
|---|---|
| 28 capsule |
NICE guidelines offer the following advice: Do not offer or advise people to use to prevent another MI: There is a lack of evidence of benefit of treatment with omega 3 fatty acids. Prescribers are advised to review omega 3 fatty acids in all patients who have been prescribed this post MI with a view to stopping treatment. http://guidance.nice.org.uk/CG172
| Pack | Price |
|---|---|
| 100 capsule | |
| 28 capsule | £14.24 |
| 90 capsule |
| Pack | Price |
|---|---|
| 1000 capsule | |
| 120 capsule | |
| 160 capsule | |
| 180 capsule | |
| 28 capsule | |
| 30 capsule | |
| 45 capsule | |
| 500 capsule | |
| 60 capsule | |
| 80 capsule | |
| 90 capsule |
| Pack | Price |
|---|---|
| 150 ml | |
| 200 ml | |
| 225 ml |